

Kamal S Saini

List of Publications by Citations

Source: <https://exaly.com/author-pdf/622735/kamal-s-saini-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

1,734
citations

18
h-index

41
g-index

55
ext. papers

2,129
ext. citations

4.2
avg, IF

4.5
L-index

#	Paper	IF	Citations
45	Dissecting the heterogeneity of triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1879-87	2.2	304
44	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013 , 39, 935-46	14.4	259
43	DNA methylation profiling reveals a predominant immune component in breast cancers. <i>EMBO Molecular Medicine</i> , 2011 , 3, 726-41	12	167
42	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020 , 139, 43-50	7.5	147
41	Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. <i>Annals of Oncology</i> , 2012 , 23, 853-9	10.3	124
40	Pertuzumab: new hope for patients with HER2-positive breast cancer. <i>Annals of Oncology</i> , 2013 , 24, 273-283	10.3	89
39	Effect of the COVID-19 pandemic on cancer treatment and research. <i>Lancet Haematology</i> , 2020 , 7, e432-e435	14.6	71
38	The AURORA initiative for metastatic breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1881-7	8.7	68
37	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. <i>Journal of Oncology</i> , 2012 , 2012, 417673	4.5	62
36	Polycythemia vera-associated pruritus and its management. <i>European Journal of Clinical Investigation</i> , 2010 , 40, 828-34	4.6	48
35	Beyond trastuzumab: new treatment options for HER2-positive breast cancer. <i>Breast</i> , 2011 , 20 Suppl 3, S20-7	3.6	46
34	Rituximab in Hodgkin lymphoma: is the target always a hit?. <i>Cancer Treatment Reviews</i> , 2011 , 37, 385-90	14.4	36
33	Genomic grade adds prognostic value in invasive lobular carcinoma. <i>Annals of Oncology</i> , 2013 , 24, 377-384	10.3	35
32	Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. <i>British Journal of Cancer</i> , 2020 , 123, 694-697	8.7	29
31	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1954-60	2.2	28
30	Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. <i>OncoTargets and Therapy</i> , 2010 , 4, 1-11	4.4	22
29	Targeted therapies in breast cancer: are heart and vessels also being targeted?. <i>Breast Cancer Research</i> , 2012 , 14, 209	8.3	21

28	Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. <i>Oncologist</i> , 2013 , 18, 134-40	5.7	21
27	Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. <i>Oncology and Therapy</i> , 2020 , 8, 171-182	2.7	16
26	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103365	7	15
25	Genomic Grade Index (GGI): Feasibility in routine practice and impact on treatment decisions in early breast cancer. <i>PLoS ONE</i> , 2013 , 8, e66848	3.7	13
24	Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. <i>Oncotarget</i> , 2016 , 7, 3002-17	3.3	11
23	Prevention and management of major side effects of targeted agents in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84 Suppl 1, e79-85	7	10
22	Treatment of early-stage HER2+ breast cancer-an evolving field. <i>Ecancermedicalscience</i> , 2015 , 9, 523	2.7	8
21	Neurofibromatosis type I with breast cancer: not only for women!. <i>Hereditary Cancer in Clinical Practice</i> , 2014 , 12, 5	2.3	7
20	Benefit-risk assessment of bevacizumab in the treatment of breast cancer. <i>Drug Safety</i> , 2012 , 35, 15-25	5.1	7
19	Magnetic resonance spectroscopy in pituitary tuberculoma. <i>Singapore Medical Journal</i> , 2007 , 48, 783-6	1.9	7
18	Orbital metastasis: a rare presentation of osteosarcoma. <i>International Ophthalmology</i> , 2008 , 28, 433-6	2.2	6
17	Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (S11-070) (P181-13) 2019		6
16	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020 , 6, 1357-1362	3.7	5
15	Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. <i>British Journal of Cancer</i> , 2021 , 125, 155-163	8.7	5
14	Simultaneous occurrence of multiple myeloma and acute myeloid leukemia. <i>Turkish Journal of Haematology</i> , 2006 , 23, 209-11	0.9	5
13	Gastric diffuse large B cell lymphoma presenting as paraneoplastic cerebellar degeneration: case report and review of literature. <i>Journal of the Egyptian National Cancer Institute</i> , 2013 , 25, 231-5	1.9	4
12	Biobanking in the era of precision oncology. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015 , 36, 1-2	0.2	4
11	Challenges in launching multinational oncology clinical trials in India. <i>South Asian Journal of Cancer</i> , 2013 , 2, 44-9	0.7	4

10	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 945-962	5.4	4
9	Primary synovial sarcoma of kidney-a report of 2 cases and review of literature. <i>Journal of the Egyptian National Cancer Institute</i> , 2010 , 22, 149-53	1.9	4
8	OT1-02-04: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 411/BO25126/TOC4939g). 2011 ,		2
7	Blindness as an initial presentation of rectal cancer with brain metastases. <i>Saudi Journal of Gastroenterology</i> , 2009 , 15, 63-4	3	2
6	Skin nodules as a presenting feature of diffuse large B-cell gastric lymphoma. <i>Indian Journal of Dermatology</i> , 2008 , 53, 39-40	0.9	1
5	Galactogram for Investigation of Pathological Nipple Discharge: A Forgotten Arrow in the Radiologists' Quiver?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2018 , 39, 96-99	0.2	1
4	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021 , 148, 287-296	7.5	1
3	Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients. <i>Digital Health</i> , 2022 , 8, 205520762210999	4	0
2	Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies. <i>Blood</i> , 2020 , 136, 13-14	2.2	
1	Mortality in adult patients with solid or hematological cancers and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e18608-e18608	2.2	